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The aim of this study was to investigate peculiarities of ascorbic acid effect on radiation-induced chromosomal aberrations frequency and 
range in the cultured peripheral blood lymphocytes (PBL) of healthy donors and cancer patients depending on doses of radiation and drug, 
as well as cells radiosensitivity (in vitro). Methods: Test system of human PBL, metaphase analysis of chromosomal aberrations. Cells 
were cultivated according to the standard procedures with some modifications. PBL culture was exposed to x-ray radiation in G0- 
and G2-phases of cell cycle. Immediately after the irradiation the culture was treated with ascorbic acid in concentrations 
of 20.0–80.0 μg/ml of blood. Results: Cell culture irradiation in low dose (0.3 Gy) and treatment with ascorbic acid in therapeutic 
concentration (20.0 μg/ml of blood) resulted in radioprotective effect, decreasing overall chromosome aberrations frequency as op-
posed to radiation effects. It has been established that post-irradiation effect of ascorbic acid upon the PBL culture in concentrations 
of 40.0 and 80.0 μg/ml, which exceeding therapeutic concentration value 2 and 4 times correspondingly, increased overall chromosome 
aberrations frequency 1.4 times compared with irradiation effect in a low dose (0.3 Gy). This bears evidence of ascorbic acid co-muta-
genic activity in the range of concentrations exceeding therapeutic values. The peak of mitotic activity inhibition was observed at 2.0 Gy ir-
radiation dose. Addition ascorbic acid in therapeutic concentration increased radiation effect this number ≈ 2 times (exceeding even intact 
control value). Compared with G0-phase, co-mutagenic effect of ascorbic acid in G2-phase appears earlier, starting with dose of 1.0 Gy. 
In the blood lymphocytes of cancer patients, the level of genetic damage was increased 1.7 times after combined treatment with low dose 
irradiation and ascorbic acid in comparison with irradiation alone which suggest the co-mutagenic instead of radioprotective effect 
of ascorbic acid. Conclusions: Genome destabilization enhancement of irradiated in vitro human somatic cells under ascorbic acid effect 
is due to its co-mutagenic properties. The formation of co-mutagenic effects of ascorbic acid depend on its concentration, irradiation dose 
and the efficiency of repair processes. Co-mutagenes may pose high carcinogenic hazard at low (above background) radiation levels.
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One of the important components of primary radio-
genic cancer prevention is taking into account effect 
of co-mutagens on humans [1]. These are compounds 
that, while not having mutagenic properties of their own, 
can significantly modify (enhance) effects of known 
mutagens of chemical nature. Drugs with co-mutagenic 
properties remain understudied, since having no own 
mutagenic activity, they are not detected at geno-
toxic screening [2, 3]. To this day, no researches are 
conducted, aimed at study of co-mutagens impact 
on radiogenic, including carcinogenic, effects formation 
in human cells under the impact of low radiation doses. 
Possible co-mutagenic effects of some common drugs, 
for instance, ascorbic acid (AA), which is designated 
as “signal molecule causing specific activity in cells”, 
are of high scientific and practical interest [4]. In series 
of studies, ambiguous effect of AA on human cells has 
been revealed [5–10]. It has been established that 
as opposed to the animals, AA is not produced in human 
organism, and its food deficiency contributes to the de-
velopment of gastric cancer, cancer of esophagus, 
oral cavity, cervix [6]. There is a contradictory view that 
vitamins, including AA, are impractical to use for carci-
nogenic risk [5]. Data on antitumor effect of AA at breast 
cancer [7], gastric cancer [8], prostate cancer [9] and 
other tumor localizations have been obtained. Re-
searchers fairly state that interpretation of data received 
on experimental animals on radioprotective and co-
mutagenic effects of some drugs, including vitamins-
antioxidants, is “wrong to extrapolate to human” [11]. 
Data on AA impact nature is not always confirmed even 
in methodically close studies [2].
Due to existing environmental situation in post-
Chernobyl period, probabilistic development of car-
cinogenic effects of low dose ionizing radiation (IR) 
and oncogenic hazard of increased level of chromo-
some changes in cell population, study of AA effect 
on formation of radiation-induced instability of human 
somatic cells genome is relevant.
Application of test-system of human peripheral 
blood lymphocytes (PBL), which are the most radiosen-
sitive somatic cells [12], allows to model hypothetic situ-
ations under combined irradiation and drugs effect with 
possible co-mutagenic activity on chromosome level.
It is expected that the formation of AA co-mutage-
nic effects may be specific, not only depending on its 
concentration or radiation dose, but differ signifi-
cantly in healthy donors and cancer patients cells due 
to the inhibitory effect of the pathological process 
on repair processes efficiency.
In presented study, peculiarities of AA effect on ra-
diation-induced chromosomal aberrations frequency 
and range in PBL culture of donors and cancer patients 
depending on radiation dose and drug concentration, 
as well as cells radiosensitivity, have been studied 
(research in vitro).
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MATERIALS AND METHODS
Healthy donors and cancer patients (endometrial 
cancer) (20 observations) venous blood has been cul-
tivated by semi-micro method with some modifications 
during 52 h [13]. This study was guided by regulations 
of Helsinki Declaration of the World Medical Association 
(2008), which provides informed consent of donors for 
participation in study. Study algorithm is represented 
in Fig. 1. Cells were incubated in RPMI 1640 medium 
(“Biowest”, France), containing 0.1 μg/ml PHA (M form, 
“Gibco-Invitrogen”, USA) for 52 h (last 3 h with col-
cemid (“Biowest”, France). PBL culture was exposed 
to radiation in G0- and G2-phases of cell cycle (for 0 and 
46 h of cells incubation correspondingly) on X-ray unit 
“RUM-17”. The irradiation conditions: current was 
10 mA, voltage — 200 kV, Cu filter (0.5 mm), dose 
rate — 0.89 Gy/min, studied doses range 0.3–2.0 Gy. In-
troduced in PBL culture right after irradiation at concen-
trations 20.0–80.0 μg/ml of blood that corresponded 
with therapeutic concentration, and also 2 and 4 times 
exceeding it, AA has been used as radiation effect modi-
fier. To arrest dividing lymphocytes in metaphase, col-
cemid was added 3 h prior to the harvest. Preparations 
were made according to the standard procedure. Slides 
were stained with 5% Giemsa solution (Gibco, USA). All 
slides were coded and scored blindly at 100 × magnifi-
cation under oil immersion. Metaphase analysis of cells 
was carried out in the first postradiation mitosis [14]. 
On each observation, an average 200–300 metaphases 
have been analyzed. Value mitotic index has been used 
as index of lymphocytes proliferative activity for which 
the amount of cells at mitosis stage was determined. 
Statistical analysis of obtained results was performed 
using of descriptive methods, and Student’s t-criterion 
(program Excel) [15].
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Fig. 1. A study algorithm of AA effect on the irradiated PBL 
of donors and cancer patients chromosomal level. FHA — mi-
togen; K — colcemid; F — cell fixation; IR — ionizing radiation; 
AA — ascorbic acid
RESULTS AND DISCUSSION
AA in  the studied concentrat ions range 
(20.0–80.0 μg/ml of blood) does not impact of chro-
mosome aberrations spontaneous level in lympho-
cytes of donors and corresponds to mean population 
values (2.0 ± 0.86 per 100 metaphases). Results 
fit the data of study [16], in which lack of vitamins-
antioxidants impact on spontaneous mutation process 
in human lymphocytes has been demonstrated.
When analyzing frequency of chromosome dama-
ges, induced by PBL irradiation in G0-phase of cell cycle 
(in dose range 0.3–2.0 Gy), and post-radiation impact 
of AA (in concentrations range of 20.0–80.0 μg/ml), 
modifying effect of this drug was ambiguous (Fig. 2).
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Fig. 2. Overall frequency of chromosome aberrations in PBL 
culture at combined effect of radiation and AA in therapeutic 
concentration of 20.0 μg/ml of blood
Combined with IR in low dose (0.3 Gy), AA in thera-
peutic concentration (20.0 μg/ml of blood) shows 
radioprotective effect, which manifests in overall chro-
mosome aberrations frequency decrease compared 
to effect of radiation alone (see Fig. 2). However, 
PBL irradiation in relatively high dose (2.0 Gy), under 
the impact of AA in the same concentration, shows 
potentiating of this effect — increase of chromosome 
aberrations overall frequency in ≈ 1.4 times that point 
to the co-mutagenic properties of the drug. Observed 
potentiating of radiation-induced cytogenetic effect 
occurs due to radial markers — dicentric chromo-
somes (10/100 metaphases compared with irradia-
tion — 5/100 metaphases) (Fig. 3).
Fig. 3. Microphoto of a metaphase plate with dicentric chromo-
some and pair fragment specified by the arrow (× 100)
Since formation of exchange aberrations — dicen-
trics, requires local double breaks of chromosomes, 
resulted due to irradiation, increased aberrations of such 
type output under additional AA effect can be interpreted 
as evidence of primary radial damages realization en-
hancement under the effect of studied drug.
Modification cytogenetic effects of low dose IR un-
der the AA effect in concentrations exceeding thera-
peutic values deserves special attention. It was estab-
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lished that post-radial effect of AA on the PBL culture 
in concentrations of 40.0 and 80.0 μg/ml, exceeding 
the value of therapeutic concentration in 2 and 4 times 
correspondingly, increases overall chromosome aber-
rations frequency as opposed to effect of irradiation 
in low dose (0.3 Gy) in 1.4 times (Fig. 4). This may point 
to co-mutagenic activity of AA in the concentrations 
range exceeding therapeutic values. Since irradia-
tion in low doses along with chromosome breaks may 
induce pre-mutative potential changes in the latter, 
additional effect of co-mutagens in high concentra-
tion may contribute to their realization in structural 
rearrangement of chromosomes, due to suppression 
of reparation enzymes included [17, 18]. Thus, AA anti-
oxidant depending on concentration at cells irradiation 
in low doses can manifest both radioprotective and 
co-mutagenic effects.
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Fig. 4. Overall frequency of chromosome aberrations in PBL 
culture under combined effect of low doses of radiation (0.3 Gy) 
and AA in the range of concentrations (20.0–80.0 μg/ml of blood)
Thus it can be generalized that formation of some 
drugs co-mutagenic effects in irradiated human cells 
depends on both the concentration and radiation 
dose. Considering carcinogenic hazard of low radiation 
doses the greatest threat co-mutagenesis can pose 
is at radiation levels effect without background. Forma-
tion of AA co-mutagenic effect depending on irradiation 
dose is showed on Fig 5. Applying AA in concentration 
of 20.0 μg/ml after cell irradiation in dose of 0.3 Gy, led 
to decrease of chromosome aberrations frequency 
at culture irradiation in low doses to 6.0 ± 1.4 per 
100 metaphases as opposed to 9.0 ± 0.86 dose effect, 
which confirms radioprotective properties of AA. Using 
AA in concentrations exceeding therapeutic dose value 
to in 4 times (40.0–80.0 μg/ml), shows co-mutagenic 
properties, increasing overall chromosome aberrations 
frequency compared with 0.3 Gy dose ≈ 1.4 times. Upon 
irradiating cells, co-mutagenic properties of AA are 
manifested at its concentrations exceeding therapeu-
tic value. At exposure of cells to radiation in relatively 
high dose (2.0 Gy), co-mutagenic effect of AA is kept 
regadles of changes in concentrations, increasing on av-
erage frequency of chromosomal aberrations 1.4 times 
due to chromosome type aberrations. This results are 
confirmed by the study [19] data, according to which 
in certain conditions of experiment, AA shows prooxidant 
activity and in such way provides oxidative cell damage.
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Fig. 5. Overall frequency of chromosome aberrations in PBL 
culture under combined effect of radiation (0.3–2.0 Gy) and 
AA in the range of concentrations (20.0–80.0 μg/ml of blood)
It is known that low capability of lymphocytes to sti-
m u lation by different mutagens may be the evidence 
of presence and/or induction of genetic disorders 
in cells, depression of T-lymphocytes, changes in their 
functional state, development of malignant neoplasms 
in individuals exposed to radiation [20]. Analysis of PBL 
mitotic activity under the conditions of combined ir-
radiation (0.3–2.0 Gy) and AA (20.0 μg/ml) effect 
in G0-phase of cell cycle showed the following (Fig. 6). 
Most pronounced suppression of cells mitotic activity 
was noted at irradiation in 2.0 Gy dose, and additional 
AA effect in therapeutic concentration, on the contrary, 
increased it ≈ 2 times (exceeding even intact control 
value). We suppose that this effect is due to “removal” 
of radiation-induced block (delay of mitosis) under 
the effect of this drug which shortens time of primary 
damages reparation. It is confirmed by increase of total 
chromosome aberrations frequency in these experi-
mental conditions (see Fig. 2).
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Fig. 6. Combined effect of IR (0.3–2.0 Gy) and AA (20.0 μg/ml) 
upon PBL mitotic activity
According to the paradigms of radiobiology, radio-
sensitivity of chromosomes is differentiated depending 
on phase of mitotic cycle owing to the different effec-
tiveness of repair processes [21]. Study of this drug 
co-mutagenic activity depending on cells radiosensi-
tivity presents certain scientific interest. In this regard 
similar experiments in the most radiosensitive G2-phase 
of lymphocytes cell cycle were conducted in culture 
(see Fig. 1). Analysis of registered chromosome damage 
at PBL irradiation during radiosensitive G2-phase showed 
that chromatic type aberrations, represented by deletions 
and exchanges, prevailed in the range (Fig. 7).
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Fig. 7. Microphoto of a metaphase plate with deletion, indicated 
by the arrow (× 100)
Cytogenetic analysis showed that at PBL irradiation 
with a dose of 0.3 Gy during G2-phase of the cell cycle 
the AA drug has insignificant radioprotective effect 
in therapeutic concentrations (Fig. 8).
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Fig. 8. Overall frequency of chromosome aberrations in PBL 
culture at combined effect of radiation and AA in therapeutic 
concentration of 20.0 μg/ml of blood
Compared with G0-phase, co-mutagenic ef-
fect of AA in G2-phase appears earlier, starting from 
1.0 Gy dose (18.0 ± 1.4 and 12.0 ± 1.1,  correspondingly; 
meaning potentiating of effect ≈ 1,5 times) due to higher 
cells radiosensitivity in this phase of cell cycle (see Fig. 2, 8).
Equally important are the results obtained with AA ef-
fect at the chromosomal level of cancer patients PBL 
(Fig. 9). It is shown that AA concentrations (20.0 and 
80.0 μg/ml) did not cause any increase in the cells with 
chromosome aberrations as opposed to the sponta-
neous level of chromosome aberrations (7.0 ± 0.8) 
in the patients non-irradiated PBL. However, the com-
bined action of low IR doses (0.3 Gy) and AА (20.0 and 
80.0 μg/ml of blood) in cancer patients lymphocytes 
display different co-mutagenic effects then the results 
obtained in similar experimental conditions on the donor 
cells. Combined with irradiation AA shows co-mutage nic 
effect in both drug concentrations (see Fig. 4, 9).
Scientific novelty of this findings lies in the fact 
that аt combined in vitro effect of low dose irradiation 
and AA in the therapeutic concentration in the blood 
lymphocytes of cancer patients there is an increase 
of genetic damage frequency 1.7 times as opposed 
to the irradiation effect (meaning the co-mutagenic 
instead of radioprotective effect of AA appears). 
The results come as solid proof of the repair processes 
dominant role in some drugs co-mutagenic activity 
display, in this case, at the combined effect of radiation 
(additional) radiation levels and AА.
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Fig. 9. Overall frequency of chromosome aberrations in cancer 
patients PBL culture under combined effect of low irradiation 
doses (0.3 Gy) and AA in the range of concentrations (20.0; 
80.0 μg/ml of blood)
Thus, based on cytogenetic studies, it has been 
established that co-mutagenic properties of AA can 
appear in irradiated cells depending on its concentra-
tion, value of IR dose and cells radiosensetivity. High 
co-mutagens concentrations potentiate damaging 
effect of low dose IR. We believe that individuals with 
high sensitivity to radiation and being under contact 
with sources of IR need an individual approach to use 
drugs with co-mutagenic activity in medical purposes.
CONCLUSIONS
Genome destabilization enhancement of irradiated 
in vitro human somatic cells under AA effect is due 
to its co-mutagenic properties. The formation of co- 
mutagenic effects of AA depend on its concentration, 
irradiation dose and the efficiency of repair processes. 
Co-mutagenes may pose high carcinogenic hazard 
at low (above background) radiation levels.
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